Clinical trials: Major Depressive Disorder, completed
Major Depression
Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients
In former studies of the investigators research group the investigators could also demonstrate acute inhibitory effects of the antidepressant mirtazapine on ACTH and cortisol release in normal controls (Schüle et al.
- Trial name
- NCT00953108
- Testing
- quetiapine, escitalopram
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Depression, Major Depressive Disorder
Augmented Human Intelligence in Major Depressive Disorder
Researchers are testing whether a computer program (called a clinical decision support tool) can help clinicians predict how a patient with depression will respond to antidepressant medication.
- Trial name
- NCT04355650
- Testing
- Clinical decision support tool
- Where
- 2 sites in United States
- Volunteers
- 126 people
- Sponsor
- Mayo Clinic
Major Depression
Modulation of Cognitive Control by Transcranial Direct Current Stimulation
Insufficient cognitive control over emotional distracters is characteristic for major depressive disorder (MDD). Hypoactivation of the dorsolateral prefrontal cortex (dlPFC) is associated with this deficit.
- Trial name
- NCT01652391
- Testing
- Transcranial direct current stimulation (tDCS); DC-STIMULATOR (NeuroConn GmbH, Ilmenau, Germany)
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Major Depression, Bipolar Disorder
Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.
The purpose of this project is to determine whether concurrent treatment of patients with major depression (unipolar or bipolar) with triiodothyronine (T3) and sertraline, will lead to a stronger and/or more rapid antidepressant…
- Conditions
- Major Depression, Bipolar Disorder, Unipolar Depression
- Trial name
- NCT00158990
- Testing
- triiodothyronine, sertraline
- Where
- 2 sites in United States, Israel
- Volunteers
- 220 people
- Sponsor
- Hadassah Medical Organization
Major Depressive Disorder
Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder
To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo.
- Trial name
- NCT00072774
- Testing
- DVS-233 SR
- Volunteers
- 480 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Postpartum Depression, Major Depressive Disorder
Neuropsychobiological Correlates of Sex-steroid Hormone Manipulation in Healthy Women: a Risk Model for Depression
The project aimed at identifying neuropsychobiological signatures of pharmacological sex-steroid hormone manipulations in healthy women as a risk model for depression.
- Conditions
- Postpartum Depression, Major Depressive Disorder, Postpartum Psychosis, Menopause
- Trial name
- GnRHa (NCT02661789)
- Testing
- Goserelin 3.6 mg implant
- Where
- Denmark
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Gitte Moos Knudsen
Bipolar Disorder
Evaluation of the Genetics of Bipolar Disorder
This study looks to identify genes that may affect a person's chances of developing bipolar disorder (BP) and related conditions.
- Trial name
- NCT00001174
- Where
- United States
- Volunteers
- 4,210 people
- Sponsor
- National Institute of Mental Health (NIMH)
Depressive Disorder, Bipolar Disorder
Nonconvulsive Electrotherapy: a Proof-of-concept Trial
This study involves pilot testing of a modified version of a proven treatment for mental illness. The treatment, electroconvulsive therapy (ECT) is used to treat more than 100,000 Americans yearly.
- Conditions
- Depressive Disorder, Bipolar Disorder, Schizoaffective Disorder
- Trial name
- NCT01065597
- Testing
- Nonconvulsive electrotherapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Maryland, College Park
Major Depressive Disorder
Assessing Dopamine Transporter Occupancy in the Healthy Adult Brain With Toludivenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
This study was a single-arm, non-randomized, open-label clinical study to assess dopamine transporter occupancy in the brain of healthy adults using 11C-CFT positron emission tomography (PET)
- Trial name
- NCT05905120
- Testing
- Toludivenlafaxine hydrochloride sustained-release tablets
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Shanghai Mental Health Center
Major Depressive Disorder
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Major Depressive Disorder
This study is to evaluate that (SEROQUEL®) quetiapine sustained-release is efficacious and safe in the treatment of patients with MDD.
- Trial name
- MOONSTONE (NCT00320268)
- Testing
- Quetiapine fumarate
- Where
- 37 sites in United States
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Bipolar Depression, Major Depressive Disorder
Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of lumateperone monotherapy in the treatment of patients with major depressive episodes associated with Bipolar I or…
- Trial name
- NCT04285515
- Testing
- Lumateperone
- Where
- 42 sites in United States, Bulgaria and 3 more
- Volunteers
- 488 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Depressive Disorder, Major
A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment
The primary purpose of this study is to assess the long-term safety and tolerability of esketamine nasal spray in combination with a selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI)…
- Trial name
- ESCAPE-LTE (NCT04829318)
- Testing
- Esketamine, SSRI/SNRI
- Where
- 59 sites in Argentina, Belgium and 12 more
- Volunteers
- 183 people
- Sponsor
- Janssen-Cilag Ltd.
Major Depressive Disorder
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
This is a phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of venlafaxine ER 75 mg/day (fixed dose) and venlafaxine ER 75 mg/day to 225 mg/day (flexible…
- Trial name
- NCT01441440
- Testing
- venlafaxine ER 75 mg/day (fixed dose), venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)
- Where
- 63 sites in Japan
- Volunteers
- 538 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Major Depressive Disorder, Pregnancy
Light Therapy for Depression During Pregnancy
The purpose of this study is to determine whether morning bright light therapy is an effective treatment for major depression during pregnancy compared with low-intensity placebo light therapy, when administered 60 minutes daily…
- Trial name
- NCT01043289
- Testing
- Light therapy
- Where
- Switzerland
- Volunteers
- 46 people
- Sponsor
- Psychiatric Hospital of the University of Basel
Major Depressive Disorder, Persistent Depressive Disorder
Transdiagnostic Psychotherapy for Veterans With Mood and Anxiety Disorders
Cognitive behavioral therapy (CBT) is a brief, efficient, and effective psychotherapy for individuals with depressive and anxiety disorders.
- Conditions
- Major Depressive Disorder, Persistent Depressive Disorder, Posttraumatic Stress Disorder, Panic Disorder
- Trial name
- TBT-RCT (NCT01947647)
- Testing
- Transdiagnostic Behavior Therapy, Behavioral Activation Therapy
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- VA Office of Research and Development
Major Depressive Disorder, Post-Traumatic Stress Disorder (PTSD)
PET Imaging of mGLuR5 With Drug Challenge
This study is designed to look at that involvement of a process in the brain called the glutamate system in depression. Participants will undergo a screening session, up to two functional Magnetic Resonance Imaging (fMRI) scans…
- Trial name
- NCT01691092
- Testing
- Ketamine
- Where
- 3 sites in United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Yale University
Depression
Pharmacogenetic-Directed Treatment for Major Depression
Determine if antidepressant treatment guided by pharmacogenetic algorithm and interpretive report improves outcomes when compared with standard treatment without the availability of genetic information.
- Trial name
- NCT01261364
- Testing
- GeneSightRx, Treatment as usual
- Volunteers
- 50 people
- Sponsor
- Assurex Health Inc.
Major Depressive Disorder
BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder
This study will determine the efficacy, safety, and tolerability of a once-daily (QD) dose of up to 80 mg of BTRX-246040 for 8 weeks in participants with MDD.
- Trial name
- NCT03193398
- Testing
- BTRX-246040 oral capsule(s)
- Where
- 8 sites in United States
- Volunteers
- 104 people
- Sponsor
- BlackThorn Therapeutics, Inc.
Major Depressive Episode
Depressive Symptoms and Subjective Stress in the Course of the Menstrual Cycle - an Ambulatory Assessment Study.
Background: Major changes in female sex hormone concentrations influence the development of depressive symptoms in women. This hypothesis has been thoroughly investigated with regard to the menopause, the postpartal phase and…
- Trial name
- DepCy (NCT04086316)
- Where
- Germany
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Freie Universität Berlin
Major Depressive Disorder
Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD
This study's primary objective is to compare the efficacy and tolerability of switching patients with inadequate relief on generic SSRIs to levomilnacipran versus adding a new treatment (quetiapine) to the participants' existing…
- Trial name
- NCT02720198
- Testing
- Levomilnacipran, Quetiapine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Duke University